Showing results (71-80 of 157) with videos related to
Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.Cancer Chemotherapy and Pharmacology|June 5, 2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaFrancis J Giles, Gary Guangping Shi, Jorge E Cortes, et al.Leukemia Research|April 28, 2004
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcomeAnne S Tsao, Hagop Kantarjian, Deborah Thomas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosisAlfonso Quintás-Cardama, Hagop M Kantarjian, Taghi Manshouri, et al.Clinical Lymphoma, Myeloma & Leukemia|January 15, 2013
Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicinPartow Kebriaei, Kaci Wilhelm, Farhad Ravandi, et al.Cancer|March 7, 2006
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemiaMaher Albitar, Steven J Potts, Francis J Giles, et al.Cancer|July 11, 2008
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitorsDan Jones, Deborah Thomas, C Cameron Yin, et al.Cancer|September 13, 2007
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 studyElias Jabbour, Hagop Kantarjian, Jorge Cortes, et al.American Journal of Hematology|November 20, 2014
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibodyElias Jabbour, Susan O'Brien, Xuelin Huang, et al.Blood|September 24, 2008
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemiasDan Jones, Rajyalakshmi Luthra, Jorge Cortes, et al.Pageof 16